同种异体造血干细胞移植后移植不良的发生率

Nikola Peulić, M. Todorovic-Balint, Nikola Lemajić
{"title":"同种异体造血干细胞移植后移植不良的发生率","authors":"Nikola Peulić, M. Todorovic-Balint, Nikola Lemajić","doi":"10.5937/smclk3-39627","DOIUrl":null,"url":null,"abstract":"Introduction: Poor engraftment represents one of the possible complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It presents as pancytopenia or bicytopenia, with or without complete donor chimerism. There are three entities of poor engraftment: poor graft function (PGF), graft failure (GF), and graft rejection (GR). Aim: This study aims to show the frequency of poor engraftment, as well as the frequency of all of its entities individually, among the patients of the Clinic of Hematology of the University Clinical Center of Serbia (UCCS), who underwent allo-HSCT between December 20, 2017 and December 25, 2020, for the purpose of achieving improved management and understanding of this serious complication. Materials and methods: This retrospective cohort study included 58 patients. Diagnosis of poor engraftment was confirmed by pancytopenia (cut off values: hemoglobin < 70g/L; platelet count < 20 x 109 /L; absolute neutrophil count (ANC) < 0.5 x 109 /L), for three consecutive days, as of day D+28, with the exclusion of severe graft versus host disease (GvHD) and relapse, with complete donor chimerism in PGF and with incomplete donor chimerism in GF. GR presented as acute rejection of the graft by the recipient with bone marrow aplasia or pancytopenia. Results: Poor engraftment was confirmed in 13 of 58 patients (22.4%). Patients with PGF were the majority, with 12.1% (seven patients), while patients with GF and those with GR had the same incidence of 5.2% (three patients). Overall survival for patients with poor engraftment after allo-HSCT was five months, which is significantly less than the overall survival of the patients who had good engraftment after allo-HSCT (57 months). Conclusion: The three types of poor engraftment must be precisely discriminated and diagnosed in relation to donor chimerism in order to decrease morbidity and mortality in patients, post allo-HSCT.","PeriodicalId":286220,"journal":{"name":"Srpski medicinski casopis Lekarske komore","volume":"58 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The frequency of poor engraftment after allogeneic hematopoietic stem cell transplantation\",\"authors\":\"Nikola Peulić, M. Todorovic-Balint, Nikola Lemajić\",\"doi\":\"10.5937/smclk3-39627\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Poor engraftment represents one of the possible complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It presents as pancytopenia or bicytopenia, with or without complete donor chimerism. There are three entities of poor engraftment: poor graft function (PGF), graft failure (GF), and graft rejection (GR). Aim: This study aims to show the frequency of poor engraftment, as well as the frequency of all of its entities individually, among the patients of the Clinic of Hematology of the University Clinical Center of Serbia (UCCS), who underwent allo-HSCT between December 20, 2017 and December 25, 2020, for the purpose of achieving improved management and understanding of this serious complication. Materials and methods: This retrospective cohort study included 58 patients. Diagnosis of poor engraftment was confirmed by pancytopenia (cut off values: hemoglobin < 70g/L; platelet count < 20 x 109 /L; absolute neutrophil count (ANC) < 0.5 x 109 /L), for three consecutive days, as of day D+28, with the exclusion of severe graft versus host disease (GvHD) and relapse, with complete donor chimerism in PGF and with incomplete donor chimerism in GF. GR presented as acute rejection of the graft by the recipient with bone marrow aplasia or pancytopenia. Results: Poor engraftment was confirmed in 13 of 58 patients (22.4%). Patients with PGF were the majority, with 12.1% (seven patients), while patients with GF and those with GR had the same incidence of 5.2% (three patients). Overall survival for patients with poor engraftment after allo-HSCT was five months, which is significantly less than the overall survival of the patients who had good engraftment after allo-HSCT (57 months). Conclusion: The three types of poor engraftment must be precisely discriminated and diagnosed in relation to donor chimerism in order to decrease morbidity and mortality in patients, post allo-HSCT.\",\"PeriodicalId\":286220,\"journal\":{\"name\":\"Srpski medicinski casopis Lekarske komore\",\"volume\":\"58 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Srpski medicinski casopis Lekarske komore\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/smclk3-39627\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Srpski medicinski casopis Lekarske komore","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/smclk3-39627","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

移植不良是同种异体造血干细胞移植(allo-HSCT)后可能出现的并发症之一。表现为全细胞减少或双细胞减少,伴或不伴供体完全嵌合。移植不良有三种类型:移植功能不良(PGF)、移植失败(GF)和移植排斥(GR)。目的:本研究旨在显示在2017年12月20日至2020年12月25日期间,塞尔维亚大学临床中心(UCCS)血血学诊所接受同种异体造血干细胞移植的患者中,移植不良的频率以及所有个体的频率,目的是改善对这一严重并发症的管理和理解。材料和方法:本回顾性队列研究纳入58例患者。全血细胞减少(截断值:血红蛋白< 70g/L;血小板计数< 20 × 109 /L;绝对中性粒细胞计数(ANC) < 0.5 × 109 /L),连续3天,截至D+28天,排除严重移植物抗宿主病(GvHD)和复发,PGF中完全供体嵌合和GF中不完全供体嵌合。GR表现为骨髓发育不全或全血细胞减少的受者对移植物的急性排斥反应。结果:58例患者中有13例(22.4%)种植不良。PGF患者占多数,为12.1%(7例),而GF和GR患者的发生率相同,为5.2%(3例)。同种异体移植后移植不良患者的总生存期为5个月,明显低于同种异体移植后移植良好患者的总生存期(57个月)。结论:为了降低同种异体移植术后患者的发病率和死亡率,必须准确区分和诊断三种移植不良类型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The frequency of poor engraftment after allogeneic hematopoietic stem cell transplantation
Introduction: Poor engraftment represents one of the possible complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It presents as pancytopenia or bicytopenia, with or without complete donor chimerism. There are three entities of poor engraftment: poor graft function (PGF), graft failure (GF), and graft rejection (GR). Aim: This study aims to show the frequency of poor engraftment, as well as the frequency of all of its entities individually, among the patients of the Clinic of Hematology of the University Clinical Center of Serbia (UCCS), who underwent allo-HSCT between December 20, 2017 and December 25, 2020, for the purpose of achieving improved management and understanding of this serious complication. Materials and methods: This retrospective cohort study included 58 patients. Diagnosis of poor engraftment was confirmed by pancytopenia (cut off values: hemoglobin < 70g/L; platelet count < 20 x 109 /L; absolute neutrophil count (ANC) < 0.5 x 109 /L), for three consecutive days, as of day D+28, with the exclusion of severe graft versus host disease (GvHD) and relapse, with complete donor chimerism in PGF and with incomplete donor chimerism in GF. GR presented as acute rejection of the graft by the recipient with bone marrow aplasia or pancytopenia. Results: Poor engraftment was confirmed in 13 of 58 patients (22.4%). Patients with PGF were the majority, with 12.1% (seven patients), while patients with GF and those with GR had the same incidence of 5.2% (three patients). Overall survival for patients with poor engraftment after allo-HSCT was five months, which is significantly less than the overall survival of the patients who had good engraftment after allo-HSCT (57 months). Conclusion: The three types of poor engraftment must be precisely discriminated and diagnosed in relation to donor chimerism in order to decrease morbidity and mortality in patients, post allo-HSCT.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信